The Food and Drug Administration will review Repros Therapeutics Inc.'s (Nasdaq: RPRX) secondary hypogonadism treatment Androxal on Monday sending the stock price soaring 79 cents to close at $2.54.
FDA to review Repros Therapeutics' Androxal
November 27, 2015 at 14:45 PM EST